Erythropoiesis-stimulating agents (ESAs) are widely used to in treating anaemia associated with renal failure. They are also now used perioperatively to reduce the use of allogeneic blood transfusions (ABTs) in patients undergoing surgery with anticipated high blood loss. Although they can reduce the risks associated with ABT and improve quality of life, the use of ESAs is still associated with adverse effects.
Introduction
Major complex surgical procedures may be associated with substantial intraoperative and/or post operative blood loss. A significant number of patients that develop anaemia from blood loss will require allogeneic blood transfusions (ABTs) and this is more likely if preoperative anaemia is present -, a state that is not uncommon in certain surgical populations. Anaemia in itself can be harmful; in order to maintain systemic oxygen delivery, there is a compensatory increase in cardiac output. Even mild preoperative anaemia is independently associated with an increased risk of 30-day morbidity and mortality and postoperative complication rates in patients undergoing major noncardiac surgery 1.
Although blood transfusion, in the context of either severe anaemia or life-threatening haemorrhage, can improve oxygen delivery to various organs, its use is associated with a number of well-recogniszed risks and complications. These include infectious risks, as well as transfusion reactions, transfusion errors, immunological reactions and immune modulation 2, 3. The rise in hemoglobin (Hb) from blood transfusions are is not consistently associated with improvement in oxygen delivery or oxygen consumption. This may be due to the significantly altered properties of the stored blood, including the depletion of 2,3-DPG which causes a left shift of the oxygen dissociation curve, thus impairing the oxygen-deliveringy ability of red blood cells 4.
The concerns regarding the adverse effects of ABT have prompted reviews of transfusion practices and the development of strategies to minimizse the need. These include the implementation of restrictive transfusion protocols, use of pharmacological and non-pharmacological measures to reduce blood loss, preoperative autologous blood donation for transfusion, perioperative cell salvage, and stimulation of preoperative erythropoiesis 5, 6. This review will focus on erythropoiesis-stimulating agents (ESAs) as a component of this patient haematological strategy [CE2] . First, it will provide a narrative review on erythropoietin, including its history, formulations and regimens, is provided. Secondly, it will examine, in a semi-quantitative manner, the efficacy and safety of perioperative erythropoietin use is examined in a semiquantitative manner.
AEetiology of preoperative anaemia
In a US national audit of patients undergoing elective orthopaedic surgery, 35% of patients were found to have Hb levels < 13 g/dL at preadmission testing. Many are were [CE3] women and anemia in approximately one-third of these patients ahad beenre the result of iron deficiency, with the remaining being attributed to chronic inflammatory disease, chronic renal disease or unknown causes 7.
Patients undergoing major surgery with anticipated high blood loss often have co-morbidities, underlying chronic disease processes as well as being of advanced age. Aging is increasingly being identified as a proinflammatory state. The anaemia of chronic disease is multifactorial but is thought to be immune -driven. Cytokines induce changes [CE4] in iron homeostasis, impaired the proliferation of erythroid progenitor cells, and reduce circulating levels of erythropoietin and the life span of red blood cells. Increase uptake of iron by cells of the reticuloendothelial systems causes a diversion of iron away from the circulation. Erythropoiesis can be directly affected by the infiltration into bone marrow of microorganisms as well as tumour cells 8. Ongoing occult blood losses from gastrointestinal or urogenital cancers may also contribute.
Erythropoietin and erythropoiesis-stimulating agents
Erythropoietin is the primary regulator of erythropoiesis. It is a glycoprotein hormone naturally produced and secreted primarily by renal tubular cells with a minor hepatic contribution. Production is stimulated by tissue hypoxia or severe haemorrhagic stress, and erythropoietin binds to specific receptors on erythroid progenitor cells in the bone marrow. The ultimate effect is to increase erythropoiesis in an attempt to maintain oxygen delivery to vital organs.
In 1977, human erythropoietin was successfully purified and characteriszed from the urine of patients with aplastic anaemia. In 1985, two groups of investigators independently cloned the human erythropoietin gene, identifying the corresponding nucleotide sequences 9. Erythropoietin for clinical use is now produced by recombinant DNA technology. The first human trials using recombinant human erythropoietin (rHuEPO), which is identical to the naturally occurring erythropoietin, examined its effectiveness in correcting anaemia of chronic renal disease. These initial results demonstrated that rHuEPO could increase the haemoglobinHb level, thus removing the need for regular blood transfusion and improving the quality of life in patients requiring dialysis 10. The trial results were so impressive that rHuEPO was approved for human use in patients with chronic renal failure by the Food and Drug Administration (FDA) in June 1989 9, 11.
Erythropoietin-stimulating agents (ESAs) are given by injection to stimulate red cell production and to treat anaemia. Clinical trials have demonstrated a dose--response relationship between erythropoietin and red blood cell expansion 12. They are commercially available in several forms.
The first-generation ESAs such as Eepoetin-alfa and epoetin-beta are recombinant erythropoietin analogues, each consisting of 165 amino acids but differ only in their glycosylation.
Darbepoetin-alfa, a second-generation ESA, is a hyperglycosylated derivative of Eepoetin. It has a longer half-life and, therefore, may be administered less frequently than Eepoetin. Although these rHuEPOs act on the same erythropoietin receptor, there are some variations on the degree of glycosylation which is responsible for the differences in pharmacokinetics and pharmacodynamics between them. The newer third-generation ESAs are chemically synthesiszed, continuous erythrocyte receptor activators (CERA), with an even longer half-life than darbepoietin 13, 14.
The FDA has now extended approval of these agents for the treatment of anaemia resulting from a number of causes. These include chronic kidney failure, chemotherapy and certain treatments for Hhuman Iimmunodeficiency Vvirus (HIV). It is also used to reduce the number of blood transfusions during and after major surgery and in patients who refuse to have an allogeneic blood transfusionABT for religious reasons such as Jehovah''s Witness. The rRHuEPO used for these indications has been described as a 'promising blood-saving technique' 15. Preoperative rHuEPO gained regulatory approval in 1996 to reduce the need for ABT in anaemic patients (pre-treatment Hb of 10 g/dL to 13 g/dL) undergoing major surgery 16. It has been (along with iron, vitamin B12 and folic acid) recommended (along with iron, vitamin B12 and folic acid) as a specific medication ''that should be used instead of blood transfusion'', if the clinical condition of the patient permits sufficient time to promote erythropoiesis 11. The rRhuEPO has also been approved for use in patients undergoing autologous donation in Japan, Europe and Canada since 1993 , 1994 and 1996 respectively, and for perioperative adjuvant therapy without autologous donation in Canada and the United States since 1996 17.
Other situations relevant to the perioperative period where ESAs have been used, is to treat the anaemia associated with critically ill patients in the intensive care unit. Despite earlier trials suggesting a small decrease in ABT after administration of ESAs, a more recent multicenter trial, 
Dose and timing of treatment
The effect of rHuEPO is rapid. Within 2 to 3 days, a sustained rise in the reticulocyte index is seen and the Hcthaematocrit begins to increase. The equivalent of one unit of blood is produced by day 7, and the equivalent of 5 units is produced by day 28 20. Although several different preoperative regimens have been described, the regimen approved by the US FDA consists of four subcutaneous (s.c.) injections of epoetin-alfa, 600 U/kg of body weight, administered at 3, 2 and 1one week before surgery and again on the day of surgery 23. Weekly doses of rHuEPO are as effective as daily administration but are less expensive. Initiating therapy with a single weekly dose would seem logical, especially if therapy is commenced well before surgery 20.
The minimal effective rHuEPO dose required to reduce ABT rate in surgical patients is unknown, especially when administered together with iron, and this is reflected in the huge range of dose regimes employed by different studies. Protocols used vary from a single large dose of rHuEPO given 1one day preoperatively 24 and a subsequent smaller dose administered at the time of surgery 25, to multiple doses given at weekly intervals over a period of 3 to 4 weeks preoperatively 26,27,28. Some protocols extend into the post-operative period, whilest daily regimes administered from up to 10 days preoperatively have also been used 29, 30, 31, 32, 33, 34, 35, 36 . The individual single dose was higher in patients undergoing weekly treatment compared to those undergoing daily treatments, with the majority of those on weekly treatment having 40,000 IU/ per week and those on daily treatments receiving between 10,000 IU and 21,000 IU/ daily. Some were based on weight, while others were a set dose irrespective of any other factors. Total dose is generally higher and the duration of treatment shorter in patients treated daily compared with those treated weekly. The sustained serum levels associated with s.c. dosing are more physiological and, therefore, more effectively stimulate erythropoiesis 9, 20. This pharmacokinetic difference may explain why the majority of studies chose a rHuEPO dosing strategy using the s.c. method. It is difficult then to evaluate the relative efficacy of either i.v. or s.c. methods.
Route of administration

Co-administration of iron
Iron deficiency is considered to be the most important cause of an inadequate response to ESAs.
Erythropoietin-stimulated erythropoiesis is independent of age and gender, and the variability in response among patients is most likely attributable to iron -restricted erythropoiesis 17. Absolute iron deficiency, where total body iron stores are depleted, or functional iron deficiency can occur.
The latter, with normal ferritin levels but low transferrin saturation, is a state which occurs when increased erythron iron requirements exceed the available supply of iron. This inability to mobilize It has been demonstrated that the use of i.v. iron, with or without rHuEPO, reduced the need for allogeneic blood transfusionABTs, but stimulation of erythropoiesis seemed to be more pronounced among patients also receiving rHuEPO. For these reasons, it has been recommended that rHuEPO therapy is supported by supplementary iron either orally or intravenously. Oral iron is usually effective but i.v. supplementation should be considered for patients with low iron stores, those with a poor initial response to rHuEPO therapy or those who demonstrate increasing evidence of iron deficiency with treatment 20. Infusion of iron should take place two to three times weekly for 3 to 4 weeks. This treatment can be administered to all patients to prevent iron-deficiency during erythropoiesis 42. Whilest the majority of studies combined treatment with iron, patients were predominantly treated with oral iron rather than i.v.
However, the use of iron supplementation in anaemia is associated with potentially deleterious effects and is therefore controversial. Iron is an essential nutrient for proliferating organisms and has been linked to increased risk of developing bacteraemia. It is also associated with the formation of oxidative free radicals which can cause tissue damage and may also have immune modulation immunomodulatory effects[CE7] 43.
Evidence for of the efficacy of ESA use
A search was performed using PubUBMedED and OvidVID MEDLINE to identify all articles with erythropoietin as a text word. All the titles and abstracts found were examined for studies evaluating the use of, as well as safety and efficacy of ESAerythropoiesis stimulating agents in the perioperative setting. Studies were included if they were published in English between January 1993 and June 2013. Only randomiszed trials were included in this part of the review. Studies involving children and preoperative autologous blood donation were excluded. Of the 14 published studies included (see Table 1 On the whole, there were variations in dosage regimes and length of treatment duration between the different types of surgery. The studies looking at orthopaedic surgery generally had a weekly or daily treatment protocol that involved longer treatment duration and enrolled a larger number of patients than either cardiac or colorectal cancer surgery. In all the studies, either a minimal Hbhaemoglobin or Hcthaematocrit was required for inclusion. Where Hbhaemoglobin was part of the inclusion criteria, this ranged from above > 8.5 g/dL to 10 g/dL to below mainly < 13.5 g/dL.
Two studies did set higher Hbhaemoglobin levels at 14.5 g/dL 43 and 16 g/dL 34 and for those that used Hcthaematocrit, this was set at above 42 28, 36. Most benefit was found in patients with a baseline Hbhaemoglobin of between 10 and 13 g/dL. Where stated, all studies excluded patients with uncontrolled hypertension and history of thromboembolism.
There were few standard transfusion triggers and often relied on clinical judgement of both surgeons and anaesthetists and subjective symptoms reported by patients, whilest several adopted a clinical measure such as Hbhaemoglobin level, but this ranged from 7.5 g/dL to 11 g/dL. A restrictive transfusion trigger has been shown to be unlikely to be associated with an increased incidence of silent myocardial ischaemia or longer hospital stay, but may result in a significant reduction in ABT rate.
Three of the included studies undertaken in patients undergoing orthopaedic procedures and one in colorectal cancer surgery randomizsed patients into 3 three groups; 2 two treatment groups along with a control group 33. The 2 two treatment groups differed in dosage of rHuEPO used -; a higher and lower dose was studied.
Preoperative administration of rHuEPO was shown to reduce allogeneic blood exposure in individuals undergoing elective surgical procedures associated with significant blood loss such as joint replacement, cardiac and oncological surgery in all except three studies 29,30,31. All the studies showing a negative correlation with ABT rate were in patients undergoing colorectal surgery. In all those studies which showed a significant reduction of ABT associated with rHuEPO use, there was also a significant reduction in the mean number of units transfused in the treatment groups. In all papers that evaluated this as the primary outcome, there was also a significant increase in reticulocyte count and Hcthaematocrit.
In Among the 4 four studies that had 2 two treatment groups as well as a control group, 3 three of thesestudies showed a significant reduction in ABT in both treatment groups. In one of these studies, there was more reduction in ABT in the lower-dose group compared to the higher dose 28.
The remaining one study of the 4, despite showing a reduction of ABT use in both treatment groups, was only significant with the higher dose of rHuEPO 33.
Colorectal cancer surgery
There were 5 five randomiszed trials looking at the use of rHuEPO in colorectal cancer surgery. Of these, three studies 29,30,31 did not show a significant difference in blood transfusion rates between treatment group and control. One of these three studies did, however, show a significant reduction in the mean number of units transfused in the treatment group 31. In comparison, the two other studies 32, 33 showed a significant reduction in transfusion rates in the rHuEPO group as well as increased Hbhaemoglobin levels. The study that had 2 two treatment groups with a highdose and low -dose regime only showed a significant reduction in ABT in those treated with a higher dose of EPO 33.
The rHuEPORecombinant human erythropoietin needs to be given in combination with iron, and this is particularly important in patients undergoing cancer surgery who may be iron-deficient, although it has been suggested that the benefit of supplemental iron may be less in oncology patients due to the decreased ability for of erythropoiesis which could be related to other factors associated with malignancy. All studies involved the co-administration of iron and in all but one,43, this was done as oral supplementation. The studies that used i.v. iron showed a significant reduction in ABT in the treatment group. It appears that oncology patients respond better to i.v. than to oral iron supplementation in chemotherapy-induced anaemia treated with rHuEPO. This is thought [CE8] to be due to an absolute iron deficiency due tobecause of continuousing external losses externally but and also due to decreased gastrointestinal absorption and iron sequestration caused by increased expression of hepcidin that can occur in oncology patients, as well as poor compliance 8, 44. Due
Owing to the shorter duration of treatment prior to surgery necessitated by the urgency of these procedures, the duration of iron treatment was has also been short.
The low transfusion trigger was set at a Hbhaemoglobin level of 7.5 g/dlL and the iron deficiency in almost all patients in one of the studies may have contributed to the generally low transfusion frequency leading to a negative result 30. Another possibility for the negative results in this group was that rHuEPO was not adequately effective in stimulating haematopoiesis in patients with tumour-induced anaemia and colorectal cancer 29. The nature of cancer surgery means that any unnecessary delay would be unethical which normally means that there is a shorter preoperative time and, therefore, a shorter period of time to initiate rHuEPO treatment. In light of this, the treatment start date in these studies ranged from 4 to 10 days prior to surgery. A daily treatment regime was used in all study protocols. This, in part, may also have contributed to the heterogeneity of the results. The differences[CE9] with between the 2 two studies which showed a reduction of blood transfusion with ESA treatment is that the overall dosage of ESA administered over the treatment period was higher -; one study had the dosage of ESA for 10 days daily and the other for 7 days daily preoperatively 24, 36, 43.
Cardiac surgery
Despite all study protocols being different with regards to dosage, interval of dosing and length of time of treatment duration, they all showed a significant reduction in ABT in the treatment group as well as significant reduction in mean units of blood transfused.
Orthopaedic surgery
All these studies used relatively large sample sizes, ranging from 194 patients in one study to 695 patients in another 26. All showed a significant reduction in ABT in the ESA treatment group with several also showing a significant reduction in mean units of blood transfused in the ESA group.
Three studies utiliszed 2two treatment groups with a lower and higher dose of ESA and all showed a significant reduction in ABT in both ESA treatment groups. Dosage regimes varied from single dose to daily and weekly regimes. Total duration of treatment ranged from one single dose to 4 weeks.
Safety of erythropoietin in perioperative use
The majority of studies involving the use of perioperative erythropoietin in patients undergoing surgery were targeted at efficacy which was reflected in the primary end points being reduction in ABT or change in other haematological parameters. Perioperative administration of ESAs to surgical patients is thought to have few adverse side effects, because it is a short-term treatment and contra-indicated for patients with co-morbidities that may predispose to these side-effects. These include uncontrolled arterial hypertension, previous acute myocardial infarction or stroke, unstable angina and severe carotid stenosis and are usually cited as exclusion criteria in these studies. Doses used in perioperative treatment tend to be lower than that which have been used conventionally in the past and also for a shorter duration of time. Due Owing to the nature of expected surgical blood loss, the rise in Hb is not sustained.
Trials did report adverse effects in their sample populations including deep venous thrombosis (DVT), hypertension, infection, anastomotic breakdown and death. However, due to the low incidence of such events in the studies, no clear correlation with rHuEPO treatment could be made.
The rRhuEPO was also withheld in patients who developed any of these adverse events during the study period. A concern for EPO use is the development of thrombotic complications associated with the higher Hcthaematocrit resulting from EPO therapy. Thrombotic and vascular events, including myocardial infarction, angina, deep vein thrombosis, superficial phlebitis, and peripheral arterial thrombosis are associated with rapid increases in the Hbhaemoglobin level and the Hcthaematocrit and are of special concern in patients who are managed with EPO. None of the studies clearly stated whether anticoagulation prophylaxis was routinely used in their sample population.
The safety effects of rHuEPO have been more extensively studied in other non surgical patient populations. Three large randomiszed controlled trials, the Normal Haematocrit Study 45, the
Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) Trial 46 and The Trial to
Reduce Cardiovascular Events with Aranesp Therapy (TREAT)47 46 involved patients with anaemia and chronic kidney disease. These studies showed that the use of ESAs to achieve a higher Hbhaemoglobin level rather than partial correction of anaemia, which is the most common use of ESAs in this population, was associated with significantly increased adverse events including non fatal and fatal myocardial infarction, non-fatal and fatal stroke, death and thromboembolic events.
In fact, the results were so conclusive that 2 two of the studies were halted early. In these studies, the dose of ESA was adjusted and increased if the target Hb was not achieved during monitoring. A review of these studies suggested that the increased incidence of adverse events may be related to the rapidity of increase in Hbhaemoglobin concentration and an overshoot of target concentration which may have been due to aggressive dosing. Another possibility was that these adverse effects may be due to some other consequence of ESAs such as trophic effects on vascular endothelial or smooth muscle cells 48.
Studies of the use of ESAs in critically ill patients showed that the proportion of patients who experienced thrombotic events was significantly greater with rHuEPO than placebo. However, the risk for of thrombotic events was significantly increased in patients who did not receive heparin at baseline but not among patients who did receive heparin at baseline 18.
In a large multicentere trial of 680 surgical patients scheduled for elective spine surgery, blood transfusion and patient outcomes were compared for ESA and placebo-treated cohorts. These patients did not receive anticoagulation prophylaxis for thrombotic adverse events. This study documented a higher incidence of deep vein thrombosis of 4.7% in the study group was 4.7% compared to 2.1% in control 2.1%, with the upper confidence limit for the between-group difference being 5.4%. This exceeded the predefined boundary of 4% that was required to demonstrate noninferiority 49.
In a small-scale, double-blind, placebo-controlled study involving 30 healthy male volunteers who were given rHuEPO, there was a moderate stimulation of thrombopoiesis and this has been suggested to be increased by 15%. However, rHuEPO was also thought to cause increased platelet reactivity and a thrombogenic effect on the newly synthesized platelets, which may lead to increased thrombotic events 12.
Hypertension is commonly associated with long-term rHuEPO therapy in patients with chronic renal failure. Although there seems to be a low risk of precipitating hypertension during short- 
Conclusions
Minimiszing allogeneic blood transfusionABT should be a high priority of any health care delivery system. Transfusions associated with perioperative care represent a significant proportion of blood consumed. The concept of patient blood management has recently been described and was adopted by the World Health Organiszation in 2010 as a principle to improve transfusion safety. It refers to pre-empting and significantly reducing the need for transfusion by addressing anaemia, blood loss and hypoxia as modifiable risk factors. It comprises three main factors: detection and correction of preoperative anaemia, minimiszing perioperative blood loss and optimiszing the patient''s physiological tolerance to anaemia 50. It can play a significant role in negating preoperative anaemia and augmenting the quantity of blood available for autologous transfusion.
The effect of ESAs on transfusion requirements in cancer surgery patients remains uncertain, although, in patients who underwent orthopaedic surgery, treatment with preoperative ESA reduced both the use and rate of blood transfusion. It is clear that the use of perioperative rHuEPO does reduce the number of transfusions, reduce the mean number of transfusions given, increase the reticulocyte count and increase Hbhaemoglobin levels. At present, there is no clear optimal strategy with respect to dose, timing and length of treatment. The subcutaneous s.c. route is commonly used and has pharmacokinetic advantages. Perioperative rHuEPO therapy seems to be associated with a low incidence of complications, although larger studies are necessary to define this more clearly.
There is an apparent risk of deep vein thrombosis but the risk can be ameliorated with the judicious use of anticoagulation. The 'true' cost-effectiveness of EPO treatment is thus difficult to calculate and may be a hindrance to more widespread adoption.
Expert opinion
There is evidence that the perioperative use of ESAs can reduce the need for ABTallogeneic blood transfusions in patients undergoing major surgery with high anticipated high blood loss. With the current drive to improve transfusion safety by modifying risk factors such as anaemia, blood loss and hypoxia, the targeting of anaemic patients preoperatively and the use of ESAs to stimulate erythropoiesis have been shown to have beneficial effects. The increase in haematological parameters may improve a patient''s status in order to optimisze post-operative rehabilitation, which can in turn lead to reduced hospital stay and improved quality of life.
Currently, the use of perioperative ESAs in surgery with anticipated high blood loss does not appear to be widely adopted. Whilest the evidence exists for the use of rHuEPO in the perioperative setting, it has yet to be quantified whether other types of ESAs may also be effective. Development in of the newer ESAs with their more favourable pharmacokinetic profiles may mean decreased frequency of administration and may therefore improve the practicalities of incorporating ESAs into a perioperative programme.
Many of the studies were in small numbers of patients and it is difficult to adequately assess efficacy as an end point. Safety of ESAs have mainly come from the large-scale studies in anaemic patients with chronic renal disease which have shown an increased risk of non fatal and fatal myocardial infarction, non-fatal and fatal stroke, death and thromboembolic events. It is unclear though whether these results can be extrapolated to the perioperative population. There are many differences between these 2 two groups of patients; the higher levels of Hb are not maintained as significant blood loss is expected intraoperatively in the perioperative group and the duration is of treatment is much shorter with much lower cumulative doses. The elective surgical population will also have a better functional and physiological baseline.
Well-designed prospective randomized controlled trialRCTs on a larger scale are needed to address dose, type of ESA, timing and duration of administration in order for optimal dosing strategies to be formulated. The adverse event reporting could also be more accurate.
Once an optimal dosing strategy can be agreed, it would be useful to undertake cost-effectiveness studies; there are not only the costs associated with the treatment drug itself, but also there are administration and screening costs, but these may be ameliorated by the cost savings of reduction in hospital stay as well as improvement in quality of life.
An important area for future research may be to explore further the pleiotropic effects of ESAs as well as to investigate the effects of ESAs at the cellular level as possible mechanisms to exert their adverse effects.
Given the awareness of risks and complications associated with ABTallogeneic blood transfusions, the use of perioperative ESA in surgery with anticipated high blood loss, is an important consideration.
Article highlights. Benefits of perioperative erythropoiesis stimulating agents (ESAs) include an increase in Hcthaematocrit and reticulocyte counts which lead to a reduction in ABTallogeneic blood transfusions. Reduction in ABTallogeneic blood transfusion hasve been consistently shown in randomized trials of patients undergoing orthopaedic and cardiac surgery. Use of perioperative ESAs in cancer patients hasve not consistently demonstrated a reduction in ABTallogeneic blood transfusion use.
Iron deficiency can reduce the efficacy of ESAs. The optimal dosing strategies for perioperative use have not yet been defined. ESA use in chronic renal failure patients with anaemia have shown an increase in adverse events when aiming for normalization of Hbhaemoglobin levels rather than partial correction. Adverse events associated with short -term perioperative use have not yet been quantified. This box summarizes key points contained in the article.
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